Reviva Pharmaceuticals Holdings (RVPH) AI Stock Analysis

• Market Cap: $39.83M
• Dividend Yield: N/A
• Average Volume (3M): 14.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: N/A
• EPS Growth: 58.55%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 115,058,620
• 10 Day Avg. Volume: 22,198,486
• 30 Day Avg. Volume: 14,401,288
• PEG Ratio: 0.04
• Price to Book (P/B): 73.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.60
• 1Y Price Target: $5.10
• Price Target Upside: 1278.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.36 ▼(-4.05% Downside)

The score is primarily pressured by weak financial performance (no revenue, persistent losses and cash burn, and funding/dilution risk) and bearish technicals (below key moving averages with negative MACD). Corporate events further increase financing and execution risk, while valuation signals are not informative due to negative earnings and no dividend.

Positive Factors

Low Financial Leverage

Near-zero debt materially reduces solvency and interest burden risk for a development-stage biotech. This structural balance-sheet strength lowers the probability of creditor-driven distress, giving management more optionality when timing financing or pursuing licensing and partnerships.

Late-stage Lead Asset

Brilaroxazine’s advanced clinical dataset and management’s view that the package can support an NDA provide a durable pathway to commercialization. A successful filing/approval would convert the company from spend-driven to revenue-generating, transforming cash needs and partnership leverage.

Strengthening IP and Indication Expansion

A granted European patent plus orphan designation for IPF strengthens exclusivity and supports expansion beyond schizophrenia. Durable IP protection and multiple indication pathways can extend commercial life, increase licensing value, and attract partners for late-stage development.

Negative Factors

No Revenue and Persistent Cash Burn

As a development-stage company with recurring negative operating and free cash flow, Reviva remains dependent on external financing. Persistent cash burn without product revenues raises sustained dilution risk and constrains strategic flexibility absent a material regulatory or commercial milestone.

Compressed Equity Base and Funding Risk

A sharply reduced equity cushion reflects cumulative losses and prior financings, limiting the company’s balance-sheet buffer. Structurally this increases the likelihood of further dilutive raises to fund registrational trials, which can impair shareholder value and complicate long-term capital planning.

Regulatory Requirement for Additional Phase 3

The FDA’s recommendation for a second pivotal trial materially extends development timelines and raises execution and financing risk. A new Phase 3 increases trial costs, delays potential approval and revenue, and makes successful capital sourcing critical to sustaining the registrational program.

Reviva Pharmaceuticals Holdings Business Overview & Revenue Model

Company Description

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

How the Company Makes Money

Reviva Pharmaceuticals Holdings generates revenue primarily through the development and commercialization of its drug candidates. The company relies on funding from partnerships, collaborations, and potential licensing agreements with larger pharmaceutical companies. These partnerships may include milestone payments and royalties based on the successful development and commercialization of its products. Additionally, Reviva may receive grants or research funding from governmental or non-governmental organizations to support its drug development programs. As a clinical-stage company, its revenue generation is heavily dependent on the successful advancement of its pipeline through clinical trials and achieving regulatory approvals.

Reviva Pharmaceuticals Holdings Financial Statement Overview

Summary

Development-stage profile with no reported revenue, large ongoing losses (TTM net loss about -$22.8M) and significant cash burn (TTM operating/free cash flow about -$27.9M). Low debt (TTM total debt $0) helps, and losses/burn have improved versus 2023–2024, but compressed equity and deeply negative ROE signal continued dilution/funding risk.

Income Statement

RVPH shows no reported revenue across the annual periods and in TTM (Trailing-Twelve-Months), which is common for development-stage biotech but leaves earnings fully dependent on spending levels. Losses remain large (TTM EBIT about -$22.9M; TTM net loss about -$22.8M). There is some improvement versus 2023–2024 (losses narrowed from roughly -$39M in 2023 and about -$30M in 2024), but profitability is still materially negative and visibility is limited without revenue.

Balance Sheet

The balance sheet is helped by very low debt (TTM total debt is $0; 2024 debt was modest at ~$0.46M), reducing financial leverage risk. However, equity has compressed sharply over time (from ~$28.7M in 2021 to ~$0.8M in 2024, then ~$4.5M TTM), reflecting cumulative losses and/or financing impacts. Return on equity is deeply negative (TTM roughly -205%), highlighting that current capital is not generating positive returns and the company may need additional funding to sustain operations.

Cash Flow

Cash generation is weak with consistently negative operating and free cash flow (TTM operating cash flow and free cash flow about -$27.9M; 2024 about -$33.5M). The cash burn improved versus 2024 and 2023, but it remains substantial and recurring. With ongoing negative cash flow and no revenue base shown, the company’s financial flexibility likely depends on external capital raises and careful burn management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	-724.74K
EBITDA	-22.71M	-29.88M	-39.21M	-24.11M	-10.10M	-2.33M
Net Income	-22.76M	-29.92M	-39.26M	-24.34M	-8.52M	-3.78M
Balance Sheet
Total Assets	14.33M	15.50M	23.70M	18.92M	31.40M	8.76M
Cash, Cash Equivalents and Short-Term Investments	13.18M	13.48M	23.37M	18.52M	29.69M	8.76M
Total Debt	0.00	458.15K	0.00	0.00	0.00	0.00
Total Liabilities	9.78M	14.69M	17.98M	10.53M	2.72M	3.30M
Stockholders Equity	4.55M	812.57K	5.72M	8.39M	28.69M	5.47M
Cash Flow
Free Cash Flow	-27.90M	-33.54M	-28.32M	-18.96M	-10.67M	-4.07M
Operating Cash Flow	-27.90M	-33.54M	-28.32M	-18.96M	-10.67M	-4.07M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	35.52M	23.65M	33.17M	7.79M	31.60M	12.83M

Reviva Pharmaceuticals Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVPH, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.52, and below the 200-day MA of 0.59, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 41.71 is Neutral, neither overbought nor oversold. The STOCH value of 84.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVPH.

Reviva Pharmaceuticals Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRLD	52 Neutral	$160.22M	-1.71	-103.99%	―	250.00%	15.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RVPH	44 Neutral	$39.83M	-0.80	―	―	―	58.55%
PSTV	44 Neutral	$83.53M	-0.31	―	―	-8.16%	22.44%
CVM	42 Neutral	$47.93M	-0.76	-328.04%	―	―	42.29%

Reviva Pharmaceuticals Holdings Corporate Events

Reviva plans second Phase 3 trial after FDA feedback

At its annual meeting on December 18, 2025, Reviva Pharmaceuticals shareholders elected five directors for one-year terms, ratified Baker Tilly US as the auditor for fiscal 2025, approved executive compensation, and cleared key capital-structure measures, including raising the authorized common shares from 315 million to 515 million and authorizing the board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-20 any time before December 31, 2026; sufficient votes rendered a contingency adjournment proposal unnecessary. On December 23, 2025, the company reported that following a pre-NDA meeting, the FDA recommended a second Phase 3 trial of its schizophrenia candidate brilaroxazine to strengthen efficacy and safety data before a U.S. filing, prompting Reviva to plan the RECOVER-2 registrational study for the first half of 2026, subject to financing, a step that could extend timelines but, if successfully executed, bolster the drug’s regulatory case in a competitive CNS market and underscores the company’s reliance on additional capital to advance late-stage development.

The most recent analyst rating on (RVPH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.

Reviva Pharmaceuticals Regains Nasdaq Compliance on Market Value

On October 14, 2025, Reviva Pharmaceuticals Holdings, Inc. announced it regained compliance with Nasdaq’s minimum Market Value of Listed Securities requirement, resolving a previous non-compliance issue. However, the company remains non-compliant with the Nasdaq’s minimum bid price requirement and has until November 10, 2025, to address this, considering options like a reverse stock split to meet the criteria.

The most recent analyst rating on (RVPH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.